What is the story about?
What's Happening?
Neurotech Pharmaceuticals has been granted a permanent J-Code (J3403) by the Centers for Medicare & Medicaid Services for its product ENCELTO, effective October 1, 2025. ENCELTO is an encapsulated cell-based gene therapy approved for treating idiopathic Macular Telangiectasia Type 2 (MacTel), a retinal disease causing vision loss. The J-Code facilitates billing and reimbursement, potentially increasing patient access to this FDA-approved treatment. ENCELTO uses a small capsule inserted into the eye to release therapeutic proteins, aiming to slow disease progression.
Why It's Important?
The assignment of a permanent J-Code is a critical step in making ENCELTO more accessible to patients suffering from MacTel. This development could lead to broader adoption of the therapy, providing a new treatment option for a condition with limited alternatives. The streamlined billing process may encourage healthcare providers to offer ENCELTO, potentially improving outcomes for patients with this progressive retinal disease.
What's Next?
With the J-Code in place, Neurotech is poised to expand the availability of ENCELTO across the U.S. The company will likely focus on educating healthcare providers about the therapy and its benefits. Continued monitoring of patient outcomes and potential side effects will be essential to ensure the therapy's long-term success and acceptance.
AI Generated Content
Do you find this article useful?
